Drug Profile
Axitinib ophthalmic - Clearside Biomedical
Alternative Names: Axitinib injectable suspension - Clearside Biomedical; CLS 1002; CLS-AX; CLS011ALatest Information Update: 21 Mar 2024
Price :
$50
*
At a glance
- Originator Clearside Biomedical
- Class Antineoplastics; Benzamides; Eye disorder therapies; Imidazoles; Indazoles; Pyridines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Platelet-derived growth factor beta receptor antagonists; Protein tyrosine kinase inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Wet age-related macular degeneration
Most Recent Events
- 18 Mar 2024 Clearside Biomedical plans a phase III trial for Wet age-related macular degeneration
- 16 Oct 2023 Efficacy and adverse events data from a phase I/IIa OASIS Extension trial in Wet age-related macular degeneration released by Clearside Biomedical
- 31 May 2023 Clearside Biomedical initiated a phase II ODESSEY trial for Wet age related macular degeneration (Treatment-experienced) in USA (Intraocular) (NCT05891548)